Alcon AG
NYSE:ALC
Intrinsic Value
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disor... [ Read More ]
The intrinsic value of one ALC stock under the Base Case scenario is 78.06 USD. Compared to the current market price of 78.47 USD, Alcon AG is Overvalued by 1%.
Valuation Backtest
Alcon AG
Run backtest to discover the historical profit from buying and selling ALC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Alcon AG
Current Assets | 5.6B |
Cash & Short-Term Investments | 1.1B |
Receivables | 2.1B |
Other Current Assets | 2.5B |
Non-Current Assets | 24B |
Long-Term Investments | 309m |
PP&E | 4.7B |
Intangibles | 18B |
Other Non-Current Assets | 949m |
Current Liabilities | 2.5B |
Accounts Payable | 811m |
Short-Term Debt | 5m |
Other Current Liabilities | 1.7B |
Non-Current Liabilities | 6.5B |
Long-Term Debt | 4.9B |
Other Non-Current Liabilities | 1.6B |
Earnings Waterfall
Alcon AG
Revenue
|
9.5B
USD
|
Cost of Revenue
|
-4.2B
USD
|
Gross Profit
|
5.3B
USD
|
Operating Expenses
|
-4.1B
USD
|
Operating Income
|
1.2B
USD
|
Other Expenses
|
-207m
USD
|
Net Income
|
974m
USD
|
Free Cash Flow Analysis
Alcon AG
What is Free Cash Flow?
ALC Profitability Score
Profitability Due Diligence
Alcon AG's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Alcon AG's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
ALC Solvency Score
Solvency Due Diligence
Alcon AG's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Alcon AG's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALC Price Targets Summary
Alcon AG
According to Wall Street analysts, the average 1-year price target for ALC is 94.94 USD with a low forecast of 69.78 USD and a high forecast of 114.67 USD.
Shareholder Return
ALC Price
Alcon AG
Average Annual Return | 5.32% |
Standard Deviation of Annual Returns | 23.15% |
Max Drawdown | -38% |
Market Capitalization | 35.6B CHF |
Shares Outstanding | 493 300 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. The company is headquartered in Fribourg, Fribourg and currently employs 24,389 full-time employees. The company went IPO on 2019-04-09. The firm operates mainly as an eye care device company. Alcon AG reports its activities into two segments: Surgical and Vision Care. The surgical segment provides a line of ophthalmic surgical products that enable surgeons to achieve accurate results. Its surgical portfolio includes technologies and devices for cataract, retinal, refractive surgery, as well as advanced technology intraocular lenses (ATIOLs) to treat cataracts and refractive errors, such as presbyopia and astigmatism. The surgical segment also includes advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery. The Vision Care segment manufactures contact lenses and lens care products, such as products for dry eye, contact lens care, ocular allergies, as well as ocular vitamins and redness relievers. The firm also offers continuing education for eye care professionals.
Contact
IPO
Employees
Officers
The intrinsic value of one ALC stock under the Base Case scenario is 78.06 USD.
Compared to the current market price of 78.47 USD, Alcon AG is Overvalued by 1%.